Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
Study identifier:BY217/M2-112
ClinicalTrials.gov identifier:NCT00430729
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. A 52 weeks double blind study with 500mcg roflumilast once daily versus placebo. Ratio-Study.
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 3
Healthy volunteers
No
Study drug
Roflumilast
Sex
All
Actual Enrollment
1100
Study type
Interventional
Age
40 Years +
Date
Study Start Date: 01 Jan 2003
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
